Department of NCDs Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Shorenstein Asia-Pacific Research Center, Stanford University, Stanford, California, USA.
J Diabetes Investig. 2019 Mar;10(2):531-538. doi: 10.1111/jdi.12897. Epub 2018 Aug 17.
AIMS/INTRODUCTION: To evaluate the annual direct medical cost attributable to type 2 diabetes mellitus according to socioeconomic factors, medical conditions and complications categories.
We created uniquely detailed data from merging datasets of the local diabetes management system and the social security system in Tongxiang, China. We calculated the type 2 diabetes mellitus-related total cost and out-of-pocket cost for inpatient admissions and outpatient visits, and compared the cost for patients with or without complications by different healthcare items.
A total of 16,675 patients were eligible for analysis. The type 2 diabetes mellitus-related cost accounted for 40.6% of the overall cost. The cost per patient was estimated to be a median of 1,067 Chinese Yuan, 7,114 Chinese Yuan and 969 Chinese Yuan for inpatient and outpatient cost, respectively. The median total cost for hospital-based care was 3.69-fold higher than that for primary care. The median cost of patients with complications was 3.46-fold higher than that of those without complications. The median cost for a patient with only macrovascular, only microvascular or both macrovascular and microvascular complications were 3.13-, 3.79- and 10.95-fold higher than that of patients without complications. Pharmaceutical expenditure accounted for 51.8 and 79.7% of the total cost for patients with or without complications, respectively.
Although the type 2 diabetes mellitus-related cost per patient was relatively low, it accounted for a great proportion of the overall cost. Complications obviously aggravated the economic burden of type 2 diabetes mellitus. Proper management and the prevention of diabetes and its complications are urgently required to curtail the economic burden.
目的/引言:评估 2 型糖尿病患者的年度直接医疗费用,分析其与社会经济因素、医疗状况和并发症类别的关系。
我们整合了中国桐乡地区糖尿病管理系统和社会保障系统的数据,创建了详细的独特数据集。我们计算了 2 型糖尿病患者住院和门诊的总费用和自付费用,并根据不同的医疗项目比较了有或无并发症患者的费用。
共有 16675 名患者符合分析条件。2 型糖尿病相关费用占总费用的 40.6%。每位患者的费用估计中位数为 1067 元人民币,用于住院和门诊费用分别为 7114 元和 969 元人民币。基于医院的护理总成本是初级保健的 3.69 倍。有并发症患者的总费用中位数是无并发症患者的 3.46 倍。仅患有大血管、仅患有微血管或同时患有大血管和微血管并发症的患者的费用中位数分别是无并发症患者的 3.13 倍、3.79 倍和 10.95 倍。药物支出分别占有并发症和无并发症患者总费用的 51.8%和 79.7%。
尽管每位 2 型糖尿病患者的相关费用相对较低,但它占总费用的很大比例。并发症明显加重了 2 型糖尿病的经济负担。迫切需要适当的管理和预防糖尿病及其并发症,以减轻经济负担。